Abstract
The authors describe a patient who presented with myoglobinuria after starting cerivastatin-gemfibrozil therapy. Muscle histochemistry revealed ragged-red fibers and cytochrome c oxidase negative (COX) fibers, and biochemistry showed a defect of COX activity. Immunoblot analysis showed a 60% reduction of COX I and COX II polypeptides. Cerivastatin myotoxicity might be related to a depletion of essential metabolites needed to anchor COX subunit I to mitochondrial membrane.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Biopsy
-
Cytochrome-c Oxidase Deficiency / chemically induced*
-
Cytochrome-c Oxidase Deficiency / diagnosis
-
Female
-
Gemfibrozil / adverse effects*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hypolipidemic Agents / adverse effects*
-
Muscle Fibers, Fast-Twitch / enzymology
-
Muscle Fibers, Fast-Twitch / pathology
-
Muscle Weakness / etiology
-
Muscle, Skeletal / drug effects
-
Muscle, Skeletal / enzymology
-
Muscle, Skeletal / pathology
-
Myoglobinuria / chemically induced*
-
Myoglobinuria / diagnosis
-
Myoglobinuria / physiopathology
-
Pain / etiology
-
Pyridines / adverse effects*
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
Pyridines
-
cerivastatin
-
Gemfibrozil